CLINICAL TRIALS

Travere Therapeutics is committed to research and development of new therapies for rare diseases.

We are currently enrolling patients in the following clinical studies:

 

ACAPELLA study logo

ACAPPELLA Study

Natural History Study of Homocystinuria Caused by Cystathionine Beta-synthase Deficiency

Therapeutic area: HCU
Study type: Observational
Learn more: hcuconnection.com | NCT02998710

 

EPPIK logo

EPPIK Study

Sparsentan Treatment in Pediatrics with Proteinuric Glomerular Diseases (EPPIK)

Therapeutic area: FSGS; IgAN
Study type: Phase 2
Learn more: eppikclinicalstudy.com | NCT05003986

 

SPARTACUS Study

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN (SPARTACUS)

Therapeutic area: IgAN
Study type: Phase 2
Learn more: NCT05856760

 

HARMONY Study

Investigational therapy: Pegtibatinase (TVT-058)
Therapeutic area: HCU
Study type: Interventional
Learn more: NCT06247085

 

Compose

COMPOSE Study

Investigational therapy: Pegtibatinase (TVT-058)
Therapeutic area: HCU
Study type: Phase 1/2
Learn more: hcuconnection.com | NCT03406611

 

HONUS Study

Humanistic Burden of FSGS and IgAN

Therapeutic area: FSGS; IgAN
Study type: Observational
Learn more: NCT05200871
View an infographic about the HONUS Study>

Active clinical studies with completed enrollment:

duplex

DUPLEX Study

Investigational therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 3
Learn more: NCT03493685
View a visual abstract of the DUPLEX Study results>

 

PROTECT IgAN

PROTECT Study

Investigational therapy: Sparsentan
Therapeutic area: IgAN
Study type: Phase 3
Learn more: NCT03762850
View a visual abstract of the PROTECT Study results>

duet

DUET Study

Investigational Therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 2
Learn more: NCT01613118